Clinical Trial

Hematology, IMG-7289, LSD1 (Lysine-Specific Demethylase 1) Inhibitor, Essential Thrombocythemia (ET), Ph 2

Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This is a single-center, open-label investigator-initiated trial evaluating the effects of IMG-7289 administered orally once daily in patients with essential thrombocythemia.
Protocol Amendment History 10 amendments
This ClinicalTrials.gov record has been amended 10 times since 2019-09-04; most recent amendment 2025-08-25.
Status change: Completed → Active, Not Recruiting 2025-08-25
Status change: Active, Not Recruiting → Completed 2025-05-16
Status change: Recruiting → Active, Not Recruiting 2024-07-08
Status change: Not Yet Recruiting → Recruiting 2020-06-08
Trial Details
NCT Number NCT04081220
Lead Sponsor The University of Texas Health Science Center at San Antonio
Collaborators: Imago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New Jersey USA)
Conditions Thrombocythemia, Essential
Enrollment 9 participants
Start Date 2020-04-09
Primary Completion 2023-12-20 (estimated)
Study Completion 2026-12-20 (estimated)
Updated on ClinicalTrials.gov 2025-09-10